Meeting
2021 ASCO Annual Meeting
Phase I study of LBL-007, a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody in patients with advanced solid tumors.
Authors
Yuankai Shi
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
Yuankai Shi , Suxia Luo , Huan Zhou , Shengyu Zhou , Shan An , Zishu Wang , Sheng Yang , Ning Li , Xiaoli Li , Xinyi Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
CTR20210196
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2523)
DOI
10.1200/JCO.2021.39.15_suppl.2523
Abstract #
2523
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
First Author: Carlos A. Gomez-Roca
Poster
2021 ASCO Annual Meeting
A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER).
First Author: Ignacio Melero
Poster
2021 ASCO Annual Meeting
Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors.
First Author: Jason J. Luke
Poster
2019 ASCO Annual Meeting
Intravenous administration of ALKS 4230 as monotherapy and in combination with pembrolizumab in a phase I study of patients with advanced solid tumors.
First Author: Ulka N. Vaishampayan